Purchase this article with an account.
Koichiro Manabe, Rie Osaka, Yuki Nakano, Tomoyoshi Fujita, Chieko Shiragami, Kazuyuki Hirooka, Yuki Muraoka, Akihito Uji, Akitaka Tsujikawa; Metamorphopsia Associated with Branch Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5335. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To apply M-CHARTS for quantitative measurements of metamorphopsia in eyes with acute branch retinal vein occlusion (BRVO) and to elucidate the pathomorphology that causes metamorphopsia.
This prospective study consisted of 42 consecutive patients (42 eyes) with acute BRVO. Both at baseline and one month after the treatment with ranibizumab, metamorphopsia was measured with M-CHARTS, and the retinal morphological changes were examined with optical coherence tomography.
At baseline, metamorphopsia was detected in the vertical and/or horizontal directions in 29 (69.0%) eyes; the mean vertical and horizontal scores were 0.59 ± 0.57 and 0.52 ± 0.67, respectively. The maximum inner retinal thickness showed no association with the M-CHARTS score, but the M-CHARTS score was correlated with the total foveal thickness (r = 0.43, P = .004), the height of serous retinal detachment (r = 0.31, P = .047), and the maximum outer retinal thickness (r = 0.36, P = .020). One month after treatment, both the inner and outer retinal thickness substantially decreased in all eyes. However, metamorphopsia persisted in 26 (89.7%) of 29 eyes. The posttreatment M-CHARTS score was not correlated with any posttreatment morphological parameters. However, the posttreatment M-CHARTS score was weakly correlated with the baseline total foveal thickness (r = 0.35. P = .024) and closely correlated with the baseline M-CHARTS score (r = 0.78, P < .001).
Metamorphopsia associated with acute BRVO was quantified using M-CHARTS.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
This PDF is available to Subscribers Only